MOTS-C
Mitochondria-encoded exercise mimetic peptide. Activates AMPK via AICAR, improves insulin sensitivity and drives fat oxidation — independently of insulin receptor signalling. [...]
Retatrutide (LY3437943)
Triple GIP/GLP-1/glucagon receptor agonist. Phase II trial demonstrated 24.2% body weight reduction at 48 weeks — the highest ever recorded for a pharmacological agent. [...]
Semaglutide
GLP-1 receptor agonist. FDA-approved (Ozempic/Wegovy). Up to 15% weight loss in Phase III trials. Reduces cardiovascular events (SELECT trial). The benchmark for GLP-1 weight loss research. [...]
Tirzepatide
FDA-approved dual GIP/GLP-1 receptor agonist (Mounjaro/Zepbound). Up to 22.5% weight loss in SURMOUNT-1 trial. Currently the most effective approved anti-obesity medication. [...]
English 
Deutsch 
Deutsch (Österreich) 
Français 
Magyar 
Slovenčina 
Slovenščina 
Hrvatski 
Deutsch (Schweiz) 
Polski 
Čeština 
Nederlands